Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.57% is in line with its 5-year average of 0.53%, around the middle of its 5-year range (0.00%–1.28%).
As of the fiscal period ended Tuesday, June 30, 2026. 23.96% above its 12-month average of 0.46%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.57%.
DEBT TO ASSETS RATIO
0.57%
DEBT TO ASSETS RATIO AVG TTM
0.46%
DEBT TO ASSETS RATIO AVG 3Y
0.58%
DEBT TO ASSETS RATIO AVG 5Y
0.53%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+23.96%
CURRENT VS 3Y AVG
-2.35%
CURRENT VS 5Y AVG
+6.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+532.54%
vs the sector median at left
Cullinan Therapeutics, Inc.
Market Cap
$998.69M
Debt to Assets Ratio
0.57%
TTM Avg
0.46%
3Y Avg
0.58%
5Y Avg
0.53%
Market Cap
$996.65M
Debt to Assets Ratio
0.16%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$982.46M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Debt to Assets Ratio
0.28%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02B
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.09M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Debt to Assets Ratio
0.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | $998.69M | 0.57% | 0.46% | 0.58% | 0.53% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 0.16% | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 0.01% | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.03% | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | 0.01% | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 0.28% | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.02B | 0.07% | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 0.33% | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.02B | 0.02% | N/A | N/A | N/A |
Debt/Assets
0.6%
Debt/Equity
0.01
Current Ratio
8.42
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.57% |
| 2026-03-31 | 0.59% |
| 2025-12-31 | 0.60% |
| 2025-09-30 | 0.25% |
| 2025-06-30 | 0.29% |
| 2025-03-31 | 0.32% |
| 2024-12-31 | 0.35% |
| 2024-09-30 | 0.37% |
| 2024-06-30 | 0.40% |
| 2024-03-31 | 0.71% |
| 2023-12-31 | 0.74% |
| 2023-09-30 | 1.20% |
| 2023-06-30 | 1.20% |
| 2023-03-31 | 1.28% |
| 2022-12-31 | 0.92% |
| 2022-09-30 | 0.76% |
| 2022-06-30 | 0.17% |
| 2022-03-31 | 0.47% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2019-12-31 | 0.00% |
